Advertisement

Correction: FDA approves once-daily combination drug for HCV

Share This Page
FDA has approved dasabuvir–ombitasvir–paritaprevir–ritonavir (Viekira XR—AbbVie) for chronic hepatitis C virus (HCV) genotype 1 infection. The new drug contains the same ingredients as Viekira Pak; however, it offers patients a simpler drug regimen.

FDA has approved dasabuvir–ombitasvir–paritaprevir–ritonavir (Viekira XR—AbbVie) for chronic hepatitis C virus (HCV) genotype 1 infection. The new drug contains the same ingredients as Viekira Pak; however, it offers patients a simpler drug regimen. The drug is taken once a day in three oral tablets that patients take with a meal. FDA said that it approved dasabuvir–ombitasvir–paritaprevir–ritonavir on the basis of six clinical trials that established the safety and efficacy of Viekira Pak.

Ad Position: 
Bottom Center Aligned
http://www.medscape.com/viewarticle/866680

Advertisement

Related Content

block-views-related-content-block